us. as We're Thanks, progress both Tyvaso the the launch are said, best Martine, DPI we've referrals as with a commercial the and year phenomenal From a good morning, Martine was of seen Tyvaso extremely patients and standpoint, Tyvaso and DPI everyone. XXXX that among for pleased starts date. active for to
to excited the early following our across of goal in organization a rallied and the very around XXXX. was This PH-ILD of also were patients approval Unitarians goal supported. number doubling We that achieve Tyvaso the
So we're and us everyone's help years to milestone. hard reach work couple proud of the really appreciative of over last this
are having treat impact have not PH-ILD for with Importantly, in us other progressive helping and in DPI Tyvaso PAH. options, reaching reinforces the that this are this also will goal only DPI but the to Tyvaso disease which Tyvaso there patients no impact serious available
With use fits believe in the simple meaningfully both the an of inhale. load, following patient's simple expand and treprostinil DPI use in elegant open, the ease of convenience of of Tyvaso mantra the inhaled hand We the a small palm of indications. inhaler that will
like even treprostinil selexipag. like our device, profile breadth the treprostinil well us the in than and DPI and earlier agonist to by convenience reach is with inhaler our to nebulizer reference. into expand therapies partner, to using deep to of active PAH able and move cartridge has developed per IP efficiently tolerability deliver ingredient efficacy known of The lung The device and DPI our Tyvaso the receptor coupled positioned less DPI Tyvaso Tyvaso's one MannKind, use PH-ILD
Since X Tyvaso the prescribers patients about or this play of we've the with prescribers We're number as in several an trends. almost their evidenced by PH-ILD seeing by out the launch, XX%, number more positive of increased increase with total prescribers our XX%, by practice.
support. look product we gauge an This intra point last is at to marker
found call using start least We has physician at the they more become one product on a much of and regularly. that products, have our supporters X patients frequently what and tend to once we
making to headway up selexipag now how are XXX more have also with Tyvaso and From or quarter have and points revenue there few written of standpoint, year the key Of We're written loyal DPI X a but prescribers. selexipag very those with prescriptions. a the I XX% prescribers, wrapped highlight. XX% top pleased we're want Tyvaso, the for traditionally
relevant is most that for we're and of for the quarter to launch DPI even in and indication a fourth that First Tyvaso still mode PH-ILD for the XXXX matter.
month during underlying And historical product and the total these than on their new and the distributors product timing did size product distributors both estimated of Therefore, our pharmacy Tyvaso in such, our impact frequently rightsizing twice are patterns patient As demand, once ordering quarter. orders our more based specialty still thus between nebulized a revenues orders orders DPI. are placing and cadence. or and Tyvaso
Second, we're also product. building we're Tyvaso a as DPI launching inventory
not to So product usual our per inventory sufficient levels contractual reach distributors a are to order able yet their practice.
factors next orders. shift distributors We the will expect pharmacy type a X of over historical to quarters, specialty product normalize, and our back will cadence more several these
think business that these the a lens are seasonality to business. which we better annual to evaluate view our have we revenue prior and calls, reasons through For historical trends our and on discussed usual
utilization our assistance patient thing our with nPAP and and of Tyvaso many Tyvaso who PH-ILD year last D were nebulizer since program on to co-pays, Part Patient than for program I is has patients program is Medicare anticipated, our has high to want on last of been PAP. DPI DPI. covered The or touch transitioned the has which higher under patient -- including by PAP and
Act We D be plan continuing under anticipate many of into effect. starting that Medicare once to begin to into of Inflation go Part the Part be will and that phenomenon D in a XXXX this patients their XXXX, changes these will provisions the covered short-term and Reduction
Orenitram. continued excited therapy We that top quarter induction. year with for the launch. Orenitram prostacyclin not demonstrated also have to the can momentum lead that therapy do oral Orenitram since a see as the released induction with to when to who data of dose its in to number compared Remodulin patients Remodulin October We're fourth average EXPEDITE shift we patients about we last highest double press line ended on of the recent Turning patients
on this along year, data, this line we a manuscript meetings with present scientific at Following EXPEDITE plan the top up on study to detailing additional second peer-reviewed quarter. details the in
therapy. the our highest especially with continue widely we as finally, ever. approximately to fourth for the on The quarters was is for Remodulin treprostinil now patients Remunity available referral And pump X/X momentum to Remodulin pleased of be as any only pump of the is one the subcutaneous Remunity performance patients of Remunity gaining quarter subcu with in U.S.
ability our confident up, billion annual our by wrap of $X of patients, XXXX. of today Tyvaso to the $X So billion after the approximately to double reaching doubling run end revenue goal we're to our number rate for in
We PH-ILD expect DPI supplemented continued and revenue research Orenitram by growth uptake protocol of in drive and both and the and supported continued through growth, to PAH Remodulin other Tyvaso Tyvaso our near-term most by resilience. expedite
With that, I'll turn the Martine. to call back over
